quipazine has been researched along with Body Weight in 8 studies
Quipazine: A pharmacologic congener of serotonin that contracts smooth muscle and has actions similar to those of tricyclic antidepressants. It has been proposed as an oxytocic.
Body Weight: The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Chronic quipazine treatment had no long-term effect on body weight." | 7.66 | Effect of chronic administration of fenfluramine and quipazine on body weight gain after ovariectomy and on brain serotonin receptor binding. ( Bartness, T; Carlton, J; Rowland, N; Smith, G, 1983) |
| " Then, the authors also examined the effect of subchronic treatment for 21 days with fluoxetine on clozapine-induced hyperphagia and modulation of body weight and fat pad weights." | 3.71 | Studies on modulation of feeding behavior by atypical antipsychotics in female mice. ( Kaur, G; Kulkarni, SK, 2002) |
| " Chronic quipazine treatment had no long-term effect on body weight." | 3.66 | Effect of chronic administration of fenfluramine and quipazine on body weight gain after ovariectomy and on brain serotonin receptor binding. ( Bartness, T; Carlton, J; Rowland, N; Smith, G, 1983) |
| " In electrophysiology studies, acute administration of FMPD selectively elevated the number of spontaneously active A10 (versus A9) dopamine neurons and chronic administration selectively decreased the number of spontaneously active A10 (versus A9) dopamine neurons." | 1.33 | Preclinical pharmacology of FMPD [6-fluoro-10-[3-(2-methoxyethyl)-4-methyl-piperazin-1-yl]-2-methyl-4H-3-thia-4,9-diaza-benzo[f]azulene]: a potential novel antipsychotic with lower histamine H1 receptor affinity than olanzapine. ( Benvenga, MJ; Bymaster, FP; Calligaro, DO; Cohen, IR; Falcone, JF; Hemrick-Luecke, SK; Martin, FM; Moore, NA; Nelson, DL; Nisenbaum, LK; Rasmussen, K; Schaus, JM; Sundquist, SJ; Tupper, DE; Wiernicki, TR, 2005) |
| "Quipazine was observed to induce an increase in mouthing in neonatal rat pups, both increases and decreases in mouthing at 10-11 days of age, while exerting a depressant effect on mouthing at 16-17 days postnatally." | 1.27 | Ontogenetic transitions in the psychopharmacological response to serotonergic manipulations. ( Enters, EK; Spear, LP, 1988) |
| "Quipazine, in mice pretreated with pargyline, induced head twitches which were inhibited by methysergide but not by D,L-propranolol." | 1.26 | Evidence for the role of noradrenaline in some effects of quipazine. ( Francès, H; Lecrubier, Y; Puech, AJ; Simon, P, 1980) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (50.00) | 18.7374 |
| 1990's | 1 (12.50) | 18.2507 |
| 2000's | 3 (37.50) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Rasmussen, K | 1 |
| Benvenga, MJ | 1 |
| Bymaster, FP | 1 |
| Calligaro, DO | 1 |
| Cohen, IR | 1 |
| Falcone, JF | 1 |
| Hemrick-Luecke, SK | 1 |
| Martin, FM | 1 |
| Moore, NA | 1 |
| Nisenbaum, LK | 1 |
| Schaus, JM | 1 |
| Sundquist, SJ | 1 |
| Tupper, DE | 1 |
| Wiernicki, TR | 1 |
| Nelson, DL | 1 |
| Rowland, N | 2 |
| Carlton, J | 1 |
| Bartness, T | 1 |
| Smith, G | 1 |
| Francès, H | 1 |
| Lecrubier, Y | 1 |
| Puech, AJ | 1 |
| Simon, P | 1 |
| Antelman, SM | 1 |
| Kocan, D | 1 |
| Mok, E | 1 |
| Paquette, M | 1 |
| Thibault, L | 1 |
| Kaur, G | 1 |
| Kulkarni, SK | 1 |
| Valencia-Flores, M | 1 |
| Campos-Sepulveda, E | 1 |
| Galindo-Morales, JA | 1 |
| Lujan, M | 1 |
| Colotla, VA | 1 |
| Enters, EK | 1 |
| Spear, LP | 1 |
8 other studies available for quipazine and Body Weight
| Article | Year |
|---|---|
Preclinical pharmacology of FMPD [6-fluoro-10-[3-(2-methoxyethyl)-4-methyl-piperazin-1-yl]-2-methyl-4H-3-thia-4,9-diaza-benzo[f]azulene]: a potential novel antipsychotic with lower histamine H1 receptor affinity than olanzapine.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Antipsychotic Agents; Benzodiazepines; Body Weight; Catalep | 2005 |
Effect of chronic administration of fenfluramine and quipazine on body weight gain after ovariectomy and on brain serotonin receptor binding.
Topics: Animals; Appetite; Body Weight; Brain; Castration; Female; Fenfluramine; Muridae; Quinolines; Quipaz | 1983 |
Evidence for the role of noradrenaline in some effects of quipazine.
Topics: Animals; Apomorphine; Behavior, Animal; Body Weight; Humans; Male; Methysergide; Mice; Norepinephrin | 1980 |
Differences among 'serotonergic' anorectics in a cross-tolerance paradigm: do they all act on serotonin systems?
Topics: Animals; Appetite Depressants; Body Weight; Drug Tolerance; Fenfluramine; Male; Pyrazines; Quipazine | 1982 |
Effect of quipazine, a selective 5-HT3 agonist, on dietary self-selection of different macronutrient diets in male and female rats.
Topics: Analysis of Variance; Animals; Body Weight; Canada; Diet; Dietary Carbohydrates; Dietary Fats; Dieta | 2000 |
Studies on modulation of feeding behavior by atypical antipsychotics in female mice.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Adipose Tissue; Animals; Antipsychotic A | 2002 |
Behavioral and biochemical correlates of chronic administration of quipazine.
Topics: Animals; Body Weight; Brain; Drinking; Drug Tolerance; Eating; Male; Motor Activity; Quinolines; Qui | 1990 |
Ontogenetic transitions in the psychopharmacological response to serotonergic manipulations.
Topics: Aging; Animals; Behavior, Animal; Body Temperature; Body Weight; Dose-Response Relationship, Drug; F | 1988 |